A forum for researchers, students and applicants in the field of cyclodextrin technology
Niemann-Pick Disease Type C (NPC) is a severe neurovisceral disorder that is pathophysiologically characterized by intracellular transport abnormalities leading to
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
A paper has recently come out open-access in Biomacromolecules reporting on pH-Responsive Polymersome Microparticles as Smart Cyclodextrin-Releasing Agents (DOI: 10.1021/acs.biomac.9b01083).
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin
The annual National Niemann Pick Disease Family Conference will be held on August 15-18, 2019, in Bloomington, US. The conference
The first paper in the special issue of Nanomaterials “Nanoconstructs Based on Cyclodextrins” has been published. Mono-lactosyl β-CD (mono-Lac-β-CD) diminished
